TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01298570
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 160 mg, PO, Days 4-10 and Days 18-24 of 28 day cycle
Study: NCT03508713
Drug: disease modified antirheumatic drugs or biological agents
Normalized name: LIPID MODIFYING AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrolled patients will be treated according to the 2015 American College of Rheumatology Guideline for the Treatment of RA
Study: NCT03237819
Drug: Placebo - Concentrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: For each day of treatment, 4 ampoules of 10 ml will be distributed to the nurse in charge of the patient (4 ampoules of glucose 5% as placebo)
Study: NCT00917501
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given twice a day which will be compared to Omega 3
Study: NCT00747331
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion (saline)~Infused at the same rate (ml/h) as the experimental drug
Study: NCT02548533
Drug: AHES
Normalized name: STOMAHESIVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application on AFXL pretreated skin 15 minutes prior to the treatment.
Study: NCT01479881
Drug: TMC435
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC435, 150 mg daily for 12 days (Days 1 to 12 in treatment D).
Study: NCT02623959
Drug: Fentanyl (IV)
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl 50 mcg given by vein prior to catheter draining.
Study: NCT02623959
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Catheter is drained then Doxycycline 500 mg placed in the catheter. Catheter is capped for 1 hour and then drained again.
Study: NCT03057899
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the study period, two capsules were taken daily for 8 weeks. Placebo and TFG capsules were identical in shape, color, and taste.
Study: NCT03562533
Drug: pegylated liposomal doxorubicin (PLD) + carboplatin (CD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: carboplatin AUC 5 plus paclitaxel 175 mg/m2 every 3 weeks for at least 6 cycles
Study: NCT02445508
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01286233
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04095299
Drug: Capecitabine 825 mg/m2 twice daily on weekdays
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy
Study: NCT03093454
Drug: Lavender Essential Oil
Normalized name: Nature's Truth Lavender Essential Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lavender essential oil will be applied topically and by inhalation to the lavender group.
Study: NCT04033575
Drug: Colgate Total SF
Normalized name: Colgate Total SF Whitening Toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1100 ppm F Colgate Total Clean Mint White Paste Toothpaste is a test treatment
Study: NCT00421174
Drug: Placebo plus corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a total of eight doses of placebo over a 4-week period. The initial dose of placebo will be administered intravenously on Day 0, with subsequent doses administered subcutaneously (SQ). Dosing will be administered twice weekly over 4 consecutive weeks. The placebo will be the inert diluent used for the etanercept formulation.~Additionally, patients in both arms will receive corticosteroids (2 mg/kg/day) Day 0 through Day 7, with subsequent taper as clinically indicated.
Study: NCT00067405
Drug: Intravenous micronutrient therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00550121
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003696
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003696
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04249531
Drug: Amikacin Inhalation Dry Powder
Normalized name: amikacin Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will inhale the weeks after iv amikacin, dry powder amikacin per inhalation once 400 mg, next week once 700 mg and the last week 1000 mg
Study: NCT04249531
Drug: Amikacin Injectable Product
Normalized name: amikacin Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: patient wil receive one dose of 400 mg amikacine intravenously in week 1
Study: NCT01554683
Drug: Low/High/Placebo Dose Keppra (Levetiracetam)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Dose (2.5 mg/kg) High Dose (7.5 mg/kg) Placebo (Saline)
Study: NCT04700449
Drug: Double-Blind 0.2mg CBP-307
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg capsule oral administration
Study: NCT04700449
Drug: Double-Blind Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule oral administration
Study: NCT04700449
Drug: Double-Blind 0.1mg CBP-307
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg capsule oral administration
Study: NCT01238848
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 cc nebulized hypertonic saline + albuterol 0.25 mg/kg/day, four times a day (QID), 5 days
Study: NCT01238848
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 cc nebulized normal saline + albuterol 0.25 mg/kg/day, four times a day (QID), 5 days
Study: NCT04826510
Drug: Lithium carbonate + perospirone hydrochloride
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The stable blood lithium concentration was 0.5-1.2 mmol / L, and the dose of perospirone hydrochloride tablets was 16-36 mg / D for 8 weeks.
Study: NCT03643666
Drug: Placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: before closure of the laparoscopic entering sites the patients received instillation of 40 ml normal saline into the peritoneum
Study: NCT01751152
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single i.v. (intravenous, into the vein) dose. At week 12 the possibility to administer an additional open-label dose of NNC0114-0006 will be provided to all subjects irrespective of initial treatment allocation as long as they are not in need of rescue medication, as judged by the clinical investigator.
Study: NCT00655642
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume matched isotonic sodium chloride solution dose administered over 2 minutes through a peripheral intravenous catheter
Study: NCT00753571
Drug: Cistanche Total Glycosides
Normalized name: anthraquinone glycoside
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Cistanche Total Glycosides Cistanche Total Glycosides ,1.8g/day(6 capsules) po Qd\*9months Arms: 1 Drug: blank capsules 6 capsules po Qd\*9months~Arms: 2
Study: NCT00519337
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid, 2 g p.o. the night before surgery followed by 500mg B.I.D. for 4 post-operative days
Study: NCT00782509
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olodaterol (BI 1744) placebo inhaled orally once daily from the Respimat inhaler
Study: NCT03012477
Drug: AZD1775
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wee1 tyrosine kinase inhibitor
Study: NCT04278469
Drug: Chemotherapy Drugs, Cancer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical high and genomic low Hormone Receptor-positive early breast cancer patients with or without adjuvant chemotherapy
Study: NCT03286582
Drug: AC-203 1% Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC-203 1% ointment BID (twice daily)
Study: NCT01653665
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the randomised controlled trial may receive this placebo as a single daily subcutaneous injection. The volume will match that of the active drug.
Study: NCT00769210
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 40 mg tablet
Study: NCT00153907
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taken twice a day on days 1-14 until disease progression or unacceptable side effects occur.
Study: NCT00395226
Drug: zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: zinc sulfate 220 mg bis for 90 days
Study: NCT02624843
Drug: Ulesfia (benzyl alcohol lotion) 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: White topical lotion
Study: NCT02624843
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: White topical lotion
Study: NCT01747850
Drug: Placebo spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study subjects will gradually increase the maximal allowed dose of Placebo starting at five sprays per day for the first two days and increasing of five sprays per day until reaching the max number of 42 sprays maximal per day at end of week 2 (Day 11). The target quit date will be set at Day 21 (but subjects will be allowed to stop using cannabis before if they are willing and able to). The Placebo treatment phase will then be continued for an additional 9 weeks (the last week will be a reduction phase with the use of Placebo Spray that will be decreased by 50%). Then exposure to Placebo will be stopped (so there will be a total of 12 weeks Placebo treatment exposure).
Study: NCT01197261
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets/ day
Study: NCT02270736
Drug: NT 201 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT 201 placebo matching injection.
Study: NCT02270736
Drug: NT 201
Normalized name: Fluarix Quadrivalent 2013-2014
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT 201 injection.
Study: NCT03789214
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Sleep Medication
Study: NCT02737397
Drug: JMI-001 (SJP-304 and SJP-223)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02737397
Drug: SJP-304
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02737397
Drug: SJP-223
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02737397
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04887844
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection were applied to the most tender point in the pes anserine region by means of the soft tissue infiltration technique only once at the commencement of the treatment period. All injections were performed by the same physician.
Study: NCT02132247
Drug: Diclofenac hydroxyethylpyrrolidine
Normalized name: diclofenac hydroxyethylpyrrolidine 1.292 % Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03230851
Drug: aspirin 100mg/d therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg aspirin for at least 5 days followed by aspirin 100mg/d
Study: NCT03230851
Drug: aspirin 100mg/2d therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg aspirin for at least 5 days followed by aspirin 100mg/2d
Study: NCT03230851
Drug: aspirin 100mg/3d therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg aspirin for at least 5 days followed by aspirin 100mg/3d
Study: NCT03230851
Drug: aspirin 75mg/d therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg aspirin for at least 5 days followed by aspirin 75mg/d
Study: NCT03230851
Drug: aspirin 50mg/d therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg aspirin for at least 5 days followed by aspirin 50mg/d
Study: NCT00359086
Drug: MGCD0103
Approvals — FDA: no, EMA: no, PMDA: no
Description: MGCD0103 given orally three times per week
Study: NCT02422823
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000552
Drug: thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01451853
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules, 0 mg ebselen, twice daily, 3 days for each cycle of chemotherapy
Study: NCT03573297
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules, oral administration, once daily
Study: NCT01232595
Drug: LFF571
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00242320
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01517620
Drug: Total Glucosides Paeony Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Glucosides Paeony Capsules, oral, 0.3 gram per capsule, 3 capsules tid, 24 weeks
Study: NCT04208997
Drug: Antiarrhythmic drug
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation of amiodarone or sotalol.
Study: NCT01708161
Drug: BYL719
Approvals — FDA: no, EMA: no, PMDA: no
Description: BYL719 is a small molecule inhibiting PI3-Kinase.
Study: NCT05629949
Drug: QL1701
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg/kg administered intravenously over 90 minutes as a loading dose on Day 1, Cycle 1 then 6 mg/kg every 3 weeks for subsequent cycles.
Study: NCT03106870
Drug: Insulin Mixtard
Normalized name: insulin isophane, human / insulin, regular, human Injectable Suspension [Human Mixtard]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin dose:~* 0.7 IU/Kg (at the second trimester of pregnancy).~* 0.8 IU/Kg (at the third trimester of pregnancy). Insulin dose was raised at a rate of 1 IU for every 10 mg/dl higher than the target blood glucose concentration.
Study: NCT01644500
Drug: Placebo as Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for glimepiride is administered orally as one to three capsules daily.
Study: NCT01642979
Drug: Glucocorticoids
Normalized name: GLUCOCORTICOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoids 0.5-1mg/kg every day(prednisone)
Study: NCT01644500
Drug: Placebo as SC Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for dulaglutide is administered as one SC injection.
Study: NCT00796900
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who satisfy the inclusion/exclusion criteria of the study and who are enrolled in this study will be randomized with computer-generated grouping to either one of two groups. One group of subjects will be given dantrolene for the first episode of fever. The other group will be given placebo. Dantrolene is supplied in 70-ml vials containing 20 mg dantrolene. Dantrolene will be given in the following dose: 5 mg/kg BW given intravenously over 30 minutes. As placebo NaCl 0,9% will be used.
Study: NCT03445195
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching 1g IV solution.
Study: NCT01617577
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: vehicle (D5W or 5% dextrose solution) is administered subcutaneously daily for 5 days
Study: NCT00851487
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo was similar in colour, consistency and volume as oral amoxicillin
Study: NCT03923036
Drug: Antineoplastic Agents
Normalized name: ANTINEOPLASTIC AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure measurement to any anticancer drug in its therapeutic use for the metastatic colorectal cancer with its posology and duration (the list provided is non-limitative). Exposure to anticancer drugs for another indication than the colorectal cancer will also be collected.
Study: NCT03405207
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: identical as active drug providing by pharmaceutical company unless it is placebo
Study: NCT01138683
Drug: diuretics
Normalized name: DIURETICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bumetanide continuous infusion to reach a prescribed negative fluid balance: dose adjustment according to the diuretic response.
Study: NCT04005768
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After a stabilization period of 20 min and 10 min after the first blood collection, Placebo will be administered per os (2 tablets) in a randomized, double-blinded fashion.
Study: NCT02860052
Drug: SB208 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply once daily to one or both feet for 14 days
Study: NCT02860052
Drug: SB208 4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply once daily to one or both feet for 14 days
Study: NCT02860052
Drug: SB208 16%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply once daily to one or both feet for 14 days
Study: NCT02860052
Drug: Vehicle Gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply once daily to one or both feet for 14 days
Study: NCT03069989
Drug: GSK3008348
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for nebulisation. Available as clear colorless to pale yellow colored solution in a 5mL vial with 20 millimeter (mm) stopper and aluminium seal yellow colored solution in a 5mL vial with 20 millimeter (mm) stopper and aluminium seal.
Study: NCT03069989
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for nebulisation. Available as clear colorless to pale yellow colored solution in a 5mL vial with 20mm stopper and aluminium seal.
Study: NCT03069989
Drug: [18F]-FBA-A20FMDV2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radio-labeled peptide ligand for PET scan. Available as intravenous (IV) infusion, 20 mL.
Study: NCT02154074
Drug: general anesthesia induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: general anesthesia induction: midazolam 0.1mg/Kg, sufentanil 1ug/Kg, cisatracurium 0.15mg/Kg, and then immediatly administrate etomidate 0.2 mg/Kg
Study: NCT02154074
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: the same volume of saline + Isoflurane during operation
Study: NCT01172522
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00335413
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003052
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03122002
Drug: Drug Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: For this observation research, anti platelet drugs, statins and ect. would be used as clinical guidelines as usal, and statical ananysis of the relationship between these drugs and the final outcomes
Study: NCT03146377
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1250 mg/m2 BD orally for 1 week of a 2-week cycle (i.e. 1 week on, 1 week off)
Study: NCT04203498
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match nabiximols will be presented as an oromucosal spray containing the excipients ethanol and propylene glycol (50% v/v) with colorings and flavored with peppermint oil (0.05% v/v). Each spray will deliver 100 microliters (μL) containing no active ingredients. Placebo will be self-administered by participants as an oromucosal spray in the morning and evening, up to a maximum of 12 sprays per day for 12 weeks.
Study: NCT01474083
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-matched placebo. Oral administration.
Study: NCT04203797
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-filled syringe administered by subcutaneous (SC)
Study: NCT03882112
Drug: HIP1601 40mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dosing of HIP1601 40mg, orally
Study: NCT00120900
Drug: GW406381
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01235689
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants with normal thiopurine methyltransferase (TPMT) enzyme activity could receive oral azathioprine 2.5 mg/kg/day. In participants with intermediate TPMT enzyme activity azathioprine was initiated at a dose of 1.25 mg/kg/day. The dose of azathioprine was adjusted according to abnormalities of white blood cell (WBC) count, platelet count, liver function tests (LFTs; i.e. alanine transaminase \[ALT\], aspartate transaminase \[AST\], alkaline phosphatase), lipase, blood urea nitrogen (BUN), and serum creatinine.
Study: NCT03309618
Drug: low-dose combination of fluvastatin (10 mg) and valsartan (20 mg) (low-flu/val)
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03309618
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02305316
Drug: BIA 9-1067 non-micronized
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02305316
Drug: BIA 9-1067 micronized
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05322486
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with or without biological drugs.
Study: NCT03231475
Drug: SPH1188-11
Approvals — FDA: no, EMA: no, PMDA: no
Description: qd.po
Study: NCT00662025
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000 mg/m2, twice daily, for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles
Study: NCT02551497
Drug: CNV1014802
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00528242
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00379457
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00379457
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00930865
Drug: Bumetanide
Normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets, Oral, 1 mg, Single Dose, 7 Days
Study: NCT00670956
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLACEBO: IM x 2 doses 24 hours apart